Summary & Overview
HCPCS Level II J0703: Cefepime Hydrochloride Injection, 500 mg
HCPCS Level II code J0703 designates a 500 mg injection of cefepime hydrochloride (B. Braun), specified as not therapeutically equivalent to Maxipime. The code captures administration of this specific parenteral antibiotic product and is relevant for facility and professional billing where branded or non-equivalent cefepime formulations are used. Nationally, accurately coding for product-specific injectable antibiotics ensures appropriate identification of drug utilization, supports inventory and reimbursement processes, and distinguishes between therapeutically nonequivalent products.
Key payers in the scope of this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical settings where it is used, and the clinical context for parenteral cefepime administration. The publication presents national benchmarking context, coding considerations, and any recent policy or coverage updates when available. If specific payer coverage details or utilization benchmarks are not present in the input, those fields are noted as Data not available in the input.
Billing Code Overview
HCPCS Level II code J0703 represents an injection of cefepime hydrochloride (B. Braun), 500 mg, noted as not therapeutically equivalent to Maxipime. This code is used for billing administration of the specified intravenous antibiotic product.
-
Service type: Parenteral antimicrobial administration (injectable antibiotic)
-
Typical site of service: Hospital inpatient, hospital outpatient department, emergency department, or other outpatient infusion/infusion suite where intravenous antibiotic therapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with a history of diabetes mellitus and recent hospitalization for suspected gram-negative sepsis. He presents to the hospital inpatient unit with fever, hypotension, and positive blood cultures for a multidrug-resistant organism pending susceptibilities. The treating infectious disease clinician orders intravenous cefepime hydrochloride (J0703) 500 mg as part of empiric broad-spectrum therapy while awaiting final sensitivities. Nursing prepares and administers the drug via peripheral IV or existing central line under hospital medication administration protocols. Medication administration is documented in the electronic health record with the J0703 HCPCS Level II code for billing; supporting documentation includes indication (e.g., presumed gram-negative bacteremia), dose, route, time of administration, and consent or order by the prescribing physician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wastage discarded | Use when a single-dose vial is partially used and the remainder is discarded; report per payer policy for wastage of J0703. |